The FDA has approved Eli Lilly’s combination of Inluriyo and Verzenio for adults with ER+, HER2‑, ESR1‑mutant metastatic breast cancer whose disease progressed after hormone therapy. A late‑stage trial of 159 patients showed median progression‑free survival of 11.1 months with the combo versus 5.5 months with Inluriyo alone. The oral regimen is available now in the U.S., but it carries significant safety risks, including severe diarrhea, low white blood cell counts, lung inflammation, liver injury and embryo‑fetal toxicity.
FDA Approves Eli Lilly’s Inluriyo–Verzenio Combo for ESR1‑Mutant Advanced Breast Cancer
FILE PHOTO: A drone view shows the Eli Lilly logo on one of the company’s offices after it hit $1 trillion in market value on Friday, becoming the first drugmaker to join the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse, in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake/File Photo
The U.S. Food and Drug Administration has approved Eli Lilly’s combination of Inluriyo and Verzenio for adults with advanced, metastatic breast cancer that is estrogen receptor–positive (ER+), HER2‑negative and harbors an ESR1 mutation, the company said on Sept. 18.
Who Is Eligible? The approval covers patients whose disease has progressed after at least one course of hormone therapy and whose tumors test positive for an ESR1 mutation.
Study Evidence
The decision was supported by a randomized late‑stage trial of 159 patients. Those who received the combination of Inluriyo plus Verzenio had a median progression‑free survival of 11.1 months versus 5.5 months for patients treated with Inluriyo alone.
How The Drugs Work
- Inluriyo (oral, once daily) targets and degrades estrogen receptors that can drive growth in some breast cancers.
- Verzenio (oral, twice daily) is a CDK4/6 inhibitor that slows cancer‑cell division.
Safety And Availability
Lilly cautioned that the combination carries risks, including severe diarrhea, neutropenia (low white blood cell counts), lung inflammation, liver injury and blood clots. Inluriyo’s label also includes a warning for embryo‑fetal toxicity, meaning it may harm a developing embryo or fetus if taken during pregnancy. According to Lilly, the Inluriyo plus Verzenio regimen is available immediately in the United States.
About half of patients with ER+/HER2‑ metastatic breast cancer may develop an ESR1 mutation during or after treatment with commonly used hormone‑blocking therapies, Lilly noted.
Clinicians and patients should weigh the demonstrated progression‑free survival benefit against the known risks when considering this combination and follow appropriate monitoring guidance.
Help us improve.
